Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

← Back to all medicines

Actimorph 5 mg Orodispersible tablets

⚠ This medicine appears to have been discontinued

The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.

If you were prescribed this medicine, other products containing Morphine sulfate may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.

Active substance: Morphine sulfate

Equivalent medicines (same active substance, strength and form)

Source: electronic medicines compendium (emc)
Official leaflet: Read the PIL on emc

What it is and what it is used for

for The active substance of Actimorph Orodispersible tablets is morphine which belongs to a group of medicines called strong analgesics or 'painkillers' from the opioids group. This medicine has been prescribed by your doctor to relieve severe pain which can be adequately managed only with opioids.

What you need to know before you take it

e Actimorph Orodispersible tablets Do not take Actimorph Orodispersible tablets

  • if you are allergic to morphine or any of the other ingredients of this medicine (listed in section 6);
  • if the patient is a child under 6 months of age (see section "Children");
  • if you have breathing problems, such as obstructive airways disease or respiratory depression. Your doctor will have told you if you have these conditions. Symptoms may include breathlessness, coughing or breathing more slowly or weakly than expected;
  • if you have severe bronchial asthma;
  • if you have a head injury that causes a severe headache or makes you feel sick. This is because this medicine may make these symptoms worse or hide the extent of the head injury;
  • if you have uncontrolled epilepsy;
  • if you have recent onset liver disease;
  • if you have a disease where the small bowel (part of your gut) does not function properly (paralytic ileus), your stomach empties more slowly than it should (delayed gastric emptying) or you have sudden acute pain in your abdomen;
  • if you are taking medicines containing buprenorphine, nalbuphine and pentazocine (substances which have properties similar to those of morphine and which may reduce the effects of morphine) as well as medicines containing naltrexone, nalmefene and sodium oxybate;
  • if you are taking a type of medicine known as monoamine oxidase inhibitors, used as antidepressants (such as tranylcypromine, phenelzine, isocarboxazid, moclobemide, and linezolid), or if you have taken these medicines in the last two weeks. Warnings and precautions Tolerance, dependence, and addiction This medicine contains morphine which is an opioid medicine. Repeated use of opioids can result in the drug being less effective (you become accustomed to it, known as tolerance). Repeated use of Actimorph can also lead to dependence, abuse, and addiction, which may result in life-threatening overdose. The risk of these side effects can increase with a higher dose and longer duration of use.

Dependence or addiction can make you feel that you are no longer in control of how much medicine you need to take or how often you need to take it.

The risk of becoming dependent or addicted varies from person to person. You may have a greater risk of becoming dependent on or addicted to Actimorph if:

  • you or anyone in your family have ever abused or been dependent on alcohol, prescription medicines or illegal drugs ("addiction").
  • you are a smoker.
  • you have ever had problems with your mood (depression, anxiety, or a personality disorder) or have been treated by a psychiatrist for other mental illnesses. If you notice any of the following signs whilst taking Actimorph, it could be a sign that you have become dependent or addicted:
  • you need to take the medicine for longer than advised by your doctor
  • you need to take more than the recommended dose
  • you are using the medicine for reasons other than prescribed, for instance, 'to stay calm' or 'help you sleep'
  • you have made repeated, unsuccessful attempts to quit or control the use of the medicine
  • when you stop taking the medicine you feel unwell, and you feel better once taking the medicine again ('withdrawal effects')

If you notice any of these signs, speak to your doctor to discuss the best treatment pathway for you, including when it is appropriate to stop and how to stop safely (See section 3, If you stop taking Actimorph).

Talk to your doctor or pharmacist before taking Actimorph Orodispersible tablets, especially:

  • if you are dependent on opioids, or if you have a history of substance abuse;
  • if you have breathing problems, such as impaired lung function or decreased respiratory capacity. Symptoms may include breathlessness and coughing;
  • if you have a severe heart problem after a long-term lung disease (cor pulmonale);
  • if you have a severe headache or are feeling dizzy, as it may indicate that the pressure in your skull is increased;
  • if you have head or brain injuries;
  • if you have disturbances of consciousness;
  • if you have low blood pressure (hypotension, associated with low circulating blood volume (hypovolaemia);
  • if you have prostate problems;
  • if you have urinary tract constriction or colic of the urinary tract;
  • if you have problems with your gallbladder;
  • if you have a bowel obstruction or an inflammatory bowel disorder;
  • if you have a tumour of the adrenal gland;
  • if you have experienced weakness, fatigue, lack of appetite, nausea, vomiting or low blood pressure. This may be symptoms of low production of the hormone cortisol in the adrenal glands, and you may need to take a hormone supplement;
  • if you have inflammation of the pancreas (which can cause severe pain in the abdomen and back);
  • if you have an under-active thyroid gland (hypothyroidism), kidney or long-term liver problems, as you may need a lower dose;
  • if you suffer from, or have ever suffered from epilepsy, seizures (fits);
  • if you have a sickle cell disease and you take morphine, your doctor will closely monitor you due to a possible association with acute chest syndrome. Your doctor will closely monitor you in case of association with morphine. Actimorph Orodispersible tablets should be used with caution before and after surgery (increased risk of intestinal paralysis or respiratory depression).

Talk to your doctor or pharmacist if you experience any of the following symptoms while taking Actimorph Orodispersible tablets:

  • Increased sensitivity to pain despite the fact that you are taking increasing doses (hyperalgesia). Your doctor will decide whether you will need a change in dose or a change in strong analgesic ("painkiller"), (see section 2);
  • Weakness, fatigue, lack of appetite, nausea, vomiting or low blood pressure. This may be a symptom of the adrenals producing too little of the hormone cortisol, and you may need to take hormone supplement;
  • Loss of libido, impotence, cessation of menstruation. This may be because of decreased sex hormone production;
  • The most significant risk of opioid overdose is a flattening and slowing of breathing (respiratory depression);
  • Constipation is common under a morphine treatment. Especially if you had problems with bowel movements before you started taking it, talk to your doctor.

Acute generalized exanthematous pustulosis (AGEP) has been reported in association with Actimorph treatment. Symptoms usually occur within the first 10 days of treatment. Tell your doctor if you have ever developed a severe skin rash or skin peeling, blistering and/or mouth sores after taking Actimorph or other opioids. Stop using Actimorph and seek medical attention immediately, if you notice any of the following symptoms: blistering, widespread scaly skin or pus-filled spots together with fever.

Sleep-related breathing disorders Actimorph Orodispersible tablets can cause sleep-related breathing disorders such as sleep apnoea (breathing pauses during sleep) and sleep related hypoxemia (low oxygen level in the blood). The symptoms can include breathing pauses during sleep, night awakening due to shortness of breath, difficulties to maintain sleep or excessive drowsiness during the day. If you or another person observe these symptoms, contact your doctor. A dose reduction may be considered by your doctor. Contact your doctor if you experience severe upper abdominal pain possibly radiating to the back, nausea, vomiting or fever as this could be symptoms associated with inflammation of the pancreas (pancreatitis) and the biliary tract system. You must only take the tablets by mouth. These tablets should never be dispersed and injected as this may lead to serious side effects, which may be fatal. Elderly people This medicine should be used with caution in the elderly (see section "How to take Actimorph Orodispersible tablets"). Children Do not give this medicine to children under 6 months of age (see section "Do not take Actimorph Orodispersible tablets").

Other medicines and Actimorph Orodispersible tablets Tell your doctor if you are taking, have recently taken or might take any other medicines. This is especially important if you are taking or might take any other medicines mentioned below:

  • rifampicin to treat e.g. tuberculosis. It may reduce the effect of morphine;
  • concomitant use of Actimorph Orodispersible tablets and sedative medicines such as benzodiazepines or related medicines increases the risk of drowsiness, difficulties in breathing (respiratory depression), coma and may be life-threatening. Because of this, concomitant use should only be considered when other treatment options are not possible. However if your doctor does prescribe Actimorph Orodispersible tablets together with sedative medicines, the dose and duration of concomitant treatment should be limited by your doctor. Please tell your doctor about all sedative medicines you are taking, and follow your doctor's dose recommendation closely. It could be helpful to inform friends or relatives to be aware of the signs and symptoms stated above. Contact your doctor when experiencing such symptoms;
  • medicines which have a central, i.e. dampening effect on brain function or alcohol, it may increase the side effects of morphine;
  • medicines to help you to sleep or stay calm (for example benzodiazepines, tranquillizers, hypnotics or sedatives);
  • general anaesthetics;
  • medicines to treat psychiatric disorders (such as phenothiazines);
  • medicines to treat depression;
  • muscle relaxants as morphine can increase the effect;
  • medicines to treat high blood pressure;
  • gabapentin or pregabalin to treat epilepsy and pain due to nerve problems (neuropathic pain);
  • buprenorphine, nalbuphine or pentazocine, as well as naltrexone, nalmefene and sodium oxybate. Do not combine Actimorph Orodispersible tablets with these medicines. If you have any doubt, please talk to your doctor;
  • other strong painkillers;
  • medicines to treat depression, called monoamine oxidase inhibitors (MAOIs), or within two weeks of stopping their use (see section 2, "Do not take Actimorph Orodispersible tablets");
  • medicines used to prevent or relieve the symptoms of an allergy (antihistamines);
  • medicines to treat Parkinson's disease;
  • certain types of medicines to stop you feeling or being sick;
  • some medicines used to treat blood clots (e.g. clopidogrel, prasugrel, ticagrelor) may have delayed and decreased effect when taken together with morphine;
  • ritonavir to treat HIV;
  • cimetidine to treat stomach ulcers, indigestion or heartburn. Actimorph Orodispersible tablets with alcohol Do not drink alcohol or take any medicines containing alcohol during treatment with this medicine. Drinking alcohol during your treatment with this medicine may make you more drowsy or increase the risk of serious sides effects such as shallow breathing with the risk of stopping breathing and loss of consciousness.

Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Pregnancy This medicine should not be used as much as possible in patients who are pregnant or nursing mothers, unless your doctor deems it absolutely necessary and considers the benefit for you to be significantly greater than the risk for the child. Men and women of child-producing/child bearing potential must use reliable contraception while using Actimorph Orodispersible tablets.

If Actimorph Orodispersible tablets are used for a long time during pregnancy, there is a risk of the new-born child having withdrawal (abstinence) symptoms which should be treated by a doctor. Withdrawal (abstinence) symptoms in babies born to mothers may include high-pitched crying, irritability and restlessness, shaking (tremor), feeding difficulties and sweating. Breast-feeding You should not breast-feed during your treatment with this medicine as morphine is known to pass into breast milk.

Driving and using machines Actimorph Orodispersible tablets may cause a number of side effects such as drowsiness which could affect your ability to drive or use machines (see section 4 for a full list of side effects). These are usually most noticeable when you first start taking this medicine, or when changing to a higher dose. If you are affected, you should not drive or use machinery.

Actimorph Orodispersible tablets contains benzyl alcohol, sodium and sulphites Actimorph 1 mg Orodispersible tablets: This medicine contains 0.1 microgram benzyl alcohol in each orodispersible tablet. Actimorph 2.5 mg Orodispersible tablets: This medicine contains 0.25 microgram benzyl alcohol in each orodispersible. Actimorph 5 mg Orodispersible tablets: This medicine contains 0.5 microgram benzyl alcohol in each orodispersible tablet. Actimorph 10 mg Orodispersible tablets: This medicine contains 0.6 microgram benzyl alcohol in each orodispersible tablet. Actimorph 20 mg Orodispersible tablets: This medicine contains 0.8 microgram benzyl alcohol in each orodispersible tablet. Actimorph 30 mg Orodispersible tablets: This medicine contains 1 microgram benzyl alcohol in each orodispersible tablet. Benzyl alcohol may cause allergic reactions.

Do not use for more than a week in young children (less than 3 years old), unless advised by your doctor or pharmacist.

Ask your doctor or pharmacist for advice if you are pregnant or breast feeding. This is because large amounts of benzyl alcohol can build-up in your body and may cause side effects (called "metabolic acidosis"). Ask your doctor or pharmacist for advice if you have a liver or kidney disease. This is because large amounts of benzyl alcohol can build-up in your body and may cause side effects (called "metabolic acidosis").

This medicine contains less than 1 mmol sodium (23 mg) per orodispersible tablet, that is to say essentially 'sodium-free'. Sulphites may rarely cause severe hypersensitivity reactions and bronchospasm. This medicine contains morphine, which is listed as a doping substance. Its use can lead to positive results in anti-doping tests.

How to take it

Actimorph Orodispersible tablets Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.

Before starting treatment and regularly during treatment, your doctor will discuss with you what you may expect from using Actimorph, when and how long you need to take it, when to contact your doctor, and when you need to stop it (see also, If you stop taking Actimorph, in this section). The dose will depend on the intensity of your pain and your previous history of the need for analgesics. When treating chronic pain, dose according to a fixed shedule should be given preference. Use in adults and adolescents over 16 years The usual starting dose is 10-20 mg every 4-6 hours. Your doctor will decide how many orodispersibles tablets you should take.

If you are still in pain while taking these tablets, talk to your doctor. Do not exceed the dose recommended by your doctor. You should check with your doctor or pharmacist if you are not sure.

Use in elderly patients (over 65 years) A reduction in dose is recommended in the elderly (dose reduction such as 2.5-5 mg every 4-6 hours).

Use in patients with liver or kidney problems This medicine should be administered with particular care in patients with liver or kidney problems. Patients with a suspected delay in the gastrointestinal passage This medicine should be administered with particular care in patients with a suspected delay in the gastrointestinal passage. Use in children and adolescents

Use in adolescents: 13 to 16 years (40-60 kg) The usual starting dose is 5-20 mg every 4-6 hours. Use in children: 6 to 12 years (18-40 kg) The usual starting dose is 5-10 mg every 4-6 hours.

1 to 5 years (9-18 kg) The usual starting dose is 2.5-5 mg every 4-6 hours. over 6 months (6-9 kg) The usual starting dose is 1 mg every 4-6 hours.

Method of administration

  • Oral use.
  • Place the orodispersible tablet in the mouth. It will melt rapidly and can then be swallowed.
  • Alternatively, you may place the orodispersible tablet in a spoon with a small quantity of water before giving it to your child or to people who have difficulties to swallow. It will rapidly melt enough to be swallowed more easily. This method of administration should be used in children below the age of 6 years. Opening instructions This medicine is available in peelable, child resistant perforated unit dose blisters. Do not push the tablet through the foil.

Pull off a single dose by tearing along the perforated line on the blister and peel back the foil on the blister to expose the orodispersible tablet. Duration of treatment Do not take this medicine for longer than absolutely necessary. Any change or interruption of treatment should be made as recommended by your doctor (see section "If you stop taking Actimorph Orodispersible tablets").

If you take more Actimorph Orodispersible tablets than you should Call your doctor or hospital straight away as you may need emergency treatment in a hospital. An overdose can have consequences and can be fatal. When seeking medical attention make sure that you take this leaflet and any remaining orodispersible tablets with you to show to the doctor. People who have taken an overdose may have narrow pupils, feel very sleepy, decrease in heart rate, low blood pressure, drop of body temperature, have or get pneumonia from inhaling vomit or foreign matter (symptoms may include breathlessness, cough and fever). People who have taken an overdose may also have breathing difficulties leading to unconsciousness or even death and/or suffer from a brain disorder (known as toxic leukoencephalopathy). In more serious cases, circulatory insufficiency may occur and eventually lead to a deep coma. Muscle damage up to muscle decay can occur (possibly resulting in kidney failure). Under no circumstances should you place yourself in situations that require increased attention, such as driving. The following measures in case of overdose are recommended until a doctor arrives: Keep awake, give breathing commands, breathing aid.

If you forget to take Actimorph Orodispersible tablets If you have taken a lower dose of Actimorph Orodispersible tablets than intended or have completely forgotten to take it, this will result in insufficient or no pain relief. Do not take a double dose to make up for a forgotten dose. Do not take two doses within 4 hours. Continue the use in the recommended manner.

If you stop taking Actimorph Orodispersible tablets Do not stop treatment with Actimorph Orodispersible tablets unless agreed with your doctor. If you want to stop treatment with Actimorph Orodispersible tablets, ask your doctor how to slowly decrease the dose to avoid abstinence (withdrawal) symptoms. Withdrawal symptoms may include body aches, tremors, diarrhea, abdominal pain, nausea, flu-like symptoms, rapid heartbeat and large pupils. Psychological symptoms are a pronounced feeling of dissatisfaction, anxiety and irritability.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Stop using Actimorph and seek medical attention immediately if you notice any of the following symptoms: Severe skin reaction with blistering, widespread scaly skin, pus-filled spots together with fever. This could be a condition called Acute Generalized Exanthematous Pustulosis (AGEP).

The most serious side effect (uncommon), is a condition where you breathe more slowly or weakly than expected (respiratory depression). Tell your doctor immediately if this happens to you.

This medicine can cause allergic reactions (the frequency of serious allergic reactions is not known). Tell your doctor immediately if you get any sudden wheeziness, difficulties in breathing, dizziness, swelling of the eyelids, face or lips, rash or itching especially those covering your whole body. The most common side effects of morphine are nausea, vomiting, confusion, constipation and drowsiness.

There is a risk that you may become addicted or reliant on this medicine.

In patients treated with morphine, the following side effects have been reported:

Very common: may affect more than 1 in 10 people

  • changes in mood, mostly elevated mood (euphoric), but also disgruntled mood (dysphoric),
  • pupil constriction (narrowing of the pupil),
  • constipation (your doctor can prescribe a laxative to overcome this problem),
  • nausea, which stops after a certain time. Common: may affect up to 1 in 10 people
  • hypersensitivity,
  • thinking disturbances,
  • confusion, difficulty in sleeping,
  • mood changes (usually reduced activity, but also increased activity or hyperexcitability),
  • hallucinations,
  • dizziness, headache,
  • involuntary muscle contractions,
  • somnolence,
  • change in taste,
  • vomiting (being sick),
  • abdominal pain,
  • dry mouth,
  • loss of appetite,
  • rash, hives or itchy skin,
  • excessive sweating,
  • difficulty in passing urine (notably in case of enlarged prostate or urethral stenosis),
  • a feeling of unusual weakness,
  • generally feeling unwell, tiredness.

Uncommon: may affect up to 1 in 100 people

  • seizures, fits or convulsions,
  • unusual muscle stiffness, muscle spasms,
  • fainting/temporary loss of consciousness (syncope),
  • tingling sensation or numbness in the limbs (paresthesia),
  • a feeling of dizziness or 'spinning' (vertigo),
  • rapid or irregular heartbeat (palpitations), pulse acceleration, pulse deceleration,
  • facial flushing (redness of the face),
  • low blood pressure, high blood pressure,
  • lung œdema (fluid accumulation in the tissue and air spaces of the lungs), slow, shallow breathing (respiratory depression), respiratory discomfort (bronchospasm),
  • a condition where the bowel does not work properly (ileus),
  • increased liver enzymes (seen in a blood test),
  • swelling of the hands, ankles or feet. Rare: may affect up to 1 in 1,000 people
  • increase in pancreatic enzymes, inflammation of the pancreas (pancreatitis),
  • dull pain in the middle to upper right area of the abdomen (biliary colic). Very rare: may affect up to 1 in 10,000 people
  • overproduction of an antidiuretic hormone causing fluid retention, resulting in low level of sodium in blood, sluggishness, tiredness or confusion,
  • decrease in libido,
  • muscle tremors,
  • blurred vision, double vision and eye trembling,
  • difficulties in breathing,
  • intestinal obstruction,
  • dental diseases, but a causal connection to morphine treatment cannot be established,
  • muscle cramps, increase in muscle tension,
  • sharp pain in the lower back that radiates down the flank, which may be caused by kidney stones,
  • erectile dysfunction,
  • absence of menstrual periods,
  • chills.

Not known: frequency cannot be estimated from the available data

  • severe allergic reaction (anaphylactic reactions, anaphylactoid reactions),
  • nightmares (more especially in the elderly),
  • sedation,
  • increased intracranial pressure,
  • pain triggered by a stimulus that is normally painless (allodynia),
  • increased sensitivity to pain (hyperalgesia – see also section 2),
  • sleep apnoea (breathing pauses during sleep),
  • light-headedness,
  • heart failure,
  • hot flushes (sudden feeling of warmth),
  • decreased cough reflex,
  • accumulation of water in the lungs after rapid dose increase (pulmonary œdema),
  • medicine tolerance (when you no longer respond to a medicine in the way you did at first and takes a higher dose of the medicine to achieve the same effect),
  • symptoms of withdrawal or dependence,
  • withdrawal symptoms in babies born to mothers who have used Actimorph Orodispersible tablets in pregnancy (see section 2 "pregnancy, breastfeeding and fertility"),
  • symptoms associated with inflammation of the pancreas (pancreatitis) and the biliary tract system e.g. severe upper abdominal possibly radiating to the back, nausea, vomiting or fever. If this medicine is stopped abruptly, a withdrawal syndrome may appear: anxiety, irritability, chills, pupil dilation, hot flashes, sweating, tearing, runny nose, nausea, vomiting, abdominal pain, diarrhea, joint pain.

Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

How to store it

Actimorph Orodispersible tablets Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the blister and carton. The expiry date refers to the last day of that month. Store in the original package in order to protect from light. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

Contents of the pack and other information

What Actimorph Orodispersible tablets contain

  • The active substance is morphine sulfate. Actimorph 1 mg Orodispersible tablets contain 1 mg of morphine sulfate. Actimorph 2.5 mg Orodispersible tablets contain 2.5 mg of morphine sulfate. Actimorph 5 mg Orodispersible tablets contain 5 mg of morphine sulfate. Actimorph 10 mg Orodispersible tablets contain 10 mg of morphine sulfate. Actimorph 20 mg Orodispersible tablets contain 20 mg of morphine sulfate. Actimorph 30 mg Orodispersible tablets contain 30 mg of morphine sulfate.
  • The other ingredients are: mannitol, hydroxypropyl cellulose, microcrystalline cellulose, crospovidone type A, acesulfame potassium, orange flavour (including benzyl alcohol, sodium, sulphites), silicon dioxide, magnesium stearate.

What Actimorph Orodispersible tablets look like and contents of the pack Actimorph 1 mg Orodispersible tablets are round, convex, 5 mm of diameter, white tablets engraved "1" on one side and smooth on the other side. Actimorph 2.5 mg Orodispersible tablets are round, convex, 7 mm of diameter, white tablets engraved "2.5" on one side and smooth on the other side. Actimorph 5 mg Orodispersible tablets are round, convex, 8.5 mm of diameter, white tablets engraved "5" on one side and smooth on the other side. Actimorph 10 mg Orodispersible tablets are round, convex, 10 mm of diameter, white tablets engraved "10" on one side and smooth on the other side. Actimorph 20 mg Orodispersible tablets are round, convex, 11 mm of diameter, white tablets engraved "20" on one side and smooth on the other side. Actimorph 30 mg Orodispersible tablets are round, convex, 12 mm of diameter, white tablets engraved "30" on one side and smooth on the other side.

Actimorph Orodispersible tablets are available in packs of 56 orodispersible tablets.

Marketing Authorisation Holder and Manufacturer Marketing Authorisation Holder Ethypharm 194, Bureaux de la Colline – Bâtiment D 92213 Saint-Cloud cedex France Manufacturer Ethypharm Chemin de la poudrière 76120 Grand-Quevilly France

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder: United Kingdom: Ethypharm UK – email: [email protected]. This leaflet was last revised in 03/2025.

C14006 – XXXXX

Frequently asked questions about Actimorph 5 mg Orodispersible tablets

How do I take Actimorph 5 mg Orodispersible tablets?

Actimorph 5 mg Orodispersible tablets comes as tablet containing 5mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.

What is the active substance in Actimorph 5 mg Orodispersible tablets?

The active substance in Actimorph 5 mg Orodispersible tablets is morphine sulfate.

Are there equivalent medicines to Actimorph 5 mg Orodispersible tablets?

Medicines with the same active substance, strength and form include: MST Continus 5 mg prolonged release tablets. They are interchangeable only if your prescriber or pharmacist says so.

Where does this information come from?

This leaflet reproduces the patient information leaflet approved for Actimorph 5 mg Orodispersible tablets, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.

Can I get Actimorph 5 mg Orodispersible tablets without a prescription?

Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.

About this leaflet

The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.

Medical disclaimer: This page is for information only and does not replace advice from your doctor or pharmacist. Always read the leaflet supplied with your medicine. If you are unwell, call NHS 111; in an emergency, call 999.

Medicines with the same active substance: Morphine sulfate (45 medicines)
See every medicine containing this substance, or browse the full A–Z of active substances.
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
Technical information intended for healthcare professionals (doctors and pharmacists). The Summary of Product Characteristics (SmPC) is the official document approved by the MHRA/EMA. It does not replace the patient leaflet or a doctor’s advice.

4.1. Therapeutic indications

Severe pain which can be adequately managed only with opioids.

4.2. Posology and method of administration

Treatment goals and discontinuation

Before initiating treatment with Actimorph, a treatment strategy including treatment duration and treatment goals, and a plan for end of treatment, should be agreed together with the patient. In accordance with pain management guidelines, during treatment, there should be frequent contact between the physician and the patient to evaluate the need for continued treatment, consider discontinuation and to adjust dosages if needed. When a patient no longer requires therapy with Actimorph, it may be advisable to taper the dose gradually to prevent symptoms of withdrawal. In absence of adequate pain control, the possibility of hyperalgesia, tolerance and progression of underlying disease should be considered (see section 4.4).

Posology

Actimorph Orodispersible tablets should be administered as follows:

Population

Starting dose

Adults and adolescents over 16 years

10-20 mg of morphine sulfate every 4-6 hours

The dose should then be carefully titrated, every day if necessary, to achieve pain relief.

Patients already receiving opioids may be initiated on higher doses depending on their previous opioid experience.

If used for dose titration Actimorph Orodispersible tablets should be taken in a fixed time schedule (every 4 to 6 hours).

The correct dose for any individual patient is that which will maintain adequate analgesia with acceptable undesirable effects.

The dose can be increased under medical supervision according to the intensity of the pain the sensitivity and the previous history of analgesic requirements of the individual patient.

Duration of treatment

This medicinal product should not be used longer than necessary.

If the need for long-term pain treatment is anticipated in view of the nature and severity of the illness, the patient should be switched to prolonged-release analgesics. The total daily dose should be the same.

If used as breakthrough pain medication, the need for more than two occasions per day is usually an indication that the prolonged-release dose requires upward titration.

Actimorph Orodispersible tablets can be taken with or without food.

Correspondence between the different routes of administration

The posology of morphine varies depending on the route of administration.

Switching from a morphine pharmaceutical form to another must take conversion factors into account in order to maintain the same amount of morphine available.

The dose should be divided by 3 when patients are transferred from an oral morphine form to an intravenous form, and halved when transferred to a subcutaneous form.

Special populations

Elderly

A reduction in dose may be advisable in the elderly (dose reduction such as 2.5-5 mg every 4-6 hours).

Patients with hepatic or renal impairment

In patients with hepatic or renal impairment, Actimorph Orodispersible tablets should be administered with particular care.

Patients with suspected delayed gastrointestinal passage

In patients with suspected delayed gastrointestinal passage, Actimorph Orodispersible tablets should be administered with particular care.

Paediatric population

Population

Starting dose

Adolescents 13-16 years (40-60 kg)

5-20 mg of morphine sulfate (corresponding to about 0.1 to 0.5 mg/kg) every 4-6 hours

Children 6-12 years (18-40 kg)

5-10 mg of morphine sulfate (corresponding to about 0.1 to 0.5 mg/kg) every 4-6 hours

Children 1-5 years (9-18 kg)

2.5-5 mg of morphine sulfate (corresponding to about 0.1 to 0.5 mg/kg) every 4-6 hours

Children > 6 months (6-9 kg)

1 mg of morphine sulfate (corresponding to about 0.1 to 0.2 mg/kg) every 4-6 hours

Actimorph Orodispersible tablets are contraindicated in children under 6 months of age (see section 4.3).

Method of administration

Actimorph Orodispersible tablets are for oral use. The tablet disperses rapidly in the mouth and is then swallowed.

Alternatively, for special population such as children or patients with difficulties in swallowing, the tablet may be placed in a spoon with the addition of a small quantity of water until sufficient dispersion to allow ingestion. This method of administration should be used in children below the age of 6 years.

4.3. Contraindications

- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1,

- Children under 6 months old,

- Severe respiratory depression with hypoxia and/or hypercapnia (in absence of artificial ventilation),

- Severe bronchial asthma,

- Severe chronic obstructive pulmonary disease,

- In acute: cranial trauma and intracranial hypertension in absence of controlled ventilation,

- Uncontrolled epilepsy,

- Acute hepatic disease,

- Acute abdomen,

- Paralytic ileus,

- Delayed gastric emptying,

- Concomitant administration with opioid agonists-antagonists (e.g. buprenorphine, nalbuphine, pentazocine), opioid partial agonists (e.g. naltrexone, nalmefene), sodium oxybate,

- Concurrent administration of mono-amine oxidase inhibitors or within two weeks of discontinuation of their use.

4.4. Special warnings and precautions for use

A particularly careful medical supervision and if necessary dose reduction is recommended in the following cases:

- Dependence on opioids, patients with a history of substance abuse,

- Impaired respiratory function,

- Respiratory depression (see below),

- Sleep apnoea,

- Cor pulmonale,

- Head injury, intracranial lesions or conditions with increased intracranial pressure, if ventilation is not performed,

- Impaired consciousness,

- Hypotension with hypovolemia,

- Prostatic hyperplasia with residual urine formation (risk of bladder rupture due to urinary retention),

- Urinary tract narrowing or colic of the urinary tract,

- Biliary tract disorders,

- Obstructive and inflammatory bowel disease,

- Constipation,

- Pheochromocytoma,

- Adrenocortical insufficiency,

- Pancreatitis,

- Severely impaired renal function,

- Severely impaired hepatic function,

- Hypothyroidism,

- Epileptic seizure disorders or increased susceptibility to seizures,

- Elderly patients.

Respiratory depression

The major risk of opioid overdose is respiratory depression.

Sleep-related breathing disorders

Opioids can cause sleep-related breathing disorders including central sleep apnoea (CSA) and sleep-related hypoxemia. Opioid use increases the risk of CSA in a dose-dependent fashion. In patients who present with CSA, consider decreasing the total opioid dosage.

Risk from concomitant use of sedative medicinal products such as benzodiazepines or related medicinal products

Concomitant use of Actimorph Orodispersible tablets and sedative medicinal products, such as benzodiazepines or related medicinal products, may result in sedation, respiratory depression, coma and death. Because of these risks, concomitant prescribing with these sedative medicinal products should be reserved for patients for whom alternative treatment options are not possible. If a decision is made to prescribe Actimorph Orodispersible tablets concomitantly with sedative medicinal products, the lowest effective dose should be used, and the duration of treatment should be as short as possible.

The patients should be followed closely for signs and symptoms of respiratory depression and sedation. In this respect, it is strongly recommended to inform patients and their caregivers to be aware of these symptoms (see section 4.5).

Morphine has an abuse potential similar to other strong agonist opioids and should be used with particular caution in patients with a history of alcohol and drug abuse.

Opioid Use Disorder (abuse and dependence)

Tolerance and physical and/or psychological dependence may develop upon repeated administration of opioids such as Actimorph.

Repeated use of Actimorph can lead to Opioid Use Disorder (OUD). A higher dose and longer duration of opioid treatment, can increase the risk of developing OUD. Abuse or intentional misuse of Actimorph may result in overdose and/or death. The risk of developing OUD is increased in patients with a personal or a family history (parents or siblings) of substance use disorders (including alcohol use disorder), in current tobacco users or in patients with a personal history of other mental health disorders (eg. major depression, anxiety and personality disorders).

Before initiating treatment with Actimorph and during the treatment, treatment goals and a discontinuation plan should be agreed with the patient (see section 4.2). Before and during treatment the patient should also be informed about the risks and signs of OUD. If these signs occur, patients should be advised to contact their physician.

Patients will require monitoring for signs of drug-seeking behavior (e.g. too early requests for refills). This includes the review of concomitant opioids and psycho-active drugs (like benzodiazepines). For patients with signs and symptoms of OUD, consultation with an addiction specialist should be considered.

Abuse of oral pharmaceutical forms by parenteral administration can be expected to result in serious adverse events, which may be fatal.

Severe cutaneous adverse reactions (SCARs)

Acute generalized exanthematous pustulosis (AGEP), which can be life-threatening or fatal, has been reported in association with morphine treatment. Most of these reactions occurred within the first 10 days of treatment. Patients should be informed about the signs and symptoms of AGEP and advised to seek medical care if they experience such symptoms.

If signs and symptoms suggestive of these skin reactions appear, morphine should be withdrawn and an alternative treatment considered.

Acute chest syndrome (ACS) in patients with sickle cell disease (SCD)

Due to a possible association between ACS and morphine use in SCD patients treated with morphine during a vasoocclusive crisis, close monitoring for ACS symptoms is warranted.

Hepatobiliary disorders

Morphine may cause dysfunction and spasm of the sphincter of Oddi, thus raising intrabiliary pressure and increasing the risk of biliary tract symptoms and pancreatitis.

Pre- and postoperative use

Actimorph Orodispersible tablets should be used with caution, pre- and postoperatively, due to the increased risk of ileus or respiratory depression in the postoperative period compared to patients who are not having surgery. Due to the analgesic effect of morphine serious intra-abdominal complications such as bowel perforation can be masked.

Patients who are going to undergo additional procedures to relieve pain (eg plexus block surgery) should not receive Actimorph Orodispersible tablets within 4 hours prior to the intervention. If treatment with Actimorph Orodispersible tablets is indicated, a dose adjustment should be made based on the new post-operative requirements.

Hyperalgesia

Hyperalgesia that does not respond to a further dose increase of morphine may occur in particular in high doses. A morphine dose reduction or change in opioid may be required.

Adrenal insufficiency

Opioid analgesics may cause reversible adrenal insufficiency requiring monitoring and glucocorticoid replacement therapy. Symptoms of adrenal insufficiency may include e.g. nausea, vomiting, loss of appetite, fatigue, weakness, dizziness, or low blood pressure.

Decreased levels of sex hormones and increased prolactin levels

Opioids, such as morphine, may have a pharmacological action on the hypothalamic-pituitary or gonadal axis.

Long-term use of opioid analgesics may be associated with decreased levels of sex hormones and increased prolactin levels. Symptoms include decreased libido, impotence, or amenorrhea.

Concomitant use with rifampicin

Plasma concentrations of morphine may be reduced by rifampicin. The analgesic effect of morphine should be monitored and doses of morphine adjusted during and after treatment with rifampicin.

Oral P2Y12 inhibitor antiplatelet therapy

Within the first day of concomitant P2Y12 inhibitor and morphine treatment, reduced efficacy of P2Y12 inhibitor treatment has been observed (see section 4.5).

Actimorph 5 mg Orodispersible tablets: This medicinal product contains 0.5 microgram benzyl alcohol in each orodispersible tablet.

Benzyl alcohol may cause allergic reactions.

This medicinal product should not be used for more than a week in young children (less than 3 years old).

High quantities should be used with caution and only if necessary, especially in pregnant or breast‑feeding women and in subjects with liver or kidney impairment because of the risk of accumulation and toxicity of benzyl alcohol (metabolic acidosis).

This medicinal product contains sulphites.

May rarely cause severe hypersensitivity reactions and bronchospasm.

This medicinal product contains less than 1 mmol sodium (23 mg) per orodispersible tablet, that is to say essentially 'sodium-free'.

This medicinal product contains morphine, which is listed as a doping substance, and its use can lead to positive results in anti-doping tests.

4.5. Interaction with other medicinal products and other forms of interaction

It must be taken into account that many medicinal products or substances can add their depressant effects of the central nervous system and contribute to decrease vigilance. Medicinal products which depress the CNS include, but are not limited to: other opioids (analgesics, antitussives and substitution treatments), neuroleptics, anxiolytics, sedatives and hypnotics (including benzodiazepines), anxiolytics other than benzodiazepines (eg meprobamate), antiepileptics (including gabapentinoids, e.g., gabapentin or pregabalin), general anaesthetics (including barbiturates), antipsychotics (including phenothiazines), sedative antidepressants (eg amitriptyline, doxepin, mianserine, mirtazapine, trimipramine), sedative H1 antihistamines, muscle relaxants (eg baclofen), thalidomide, central antihypertensives, centrally acting anti-emetics and alcohol. Interactive effects resulting in respiratory depression, hypotension, profound sedation, or coma may result if these drugs are taken in combination with the usual doses of morphine.

Concomitant use contraindicated

+ Morphonic agonists-antagonists (eg buprenorphine, nalbuphine, pentazocine)

Mixed agonist/antagonist opioid analgesics should not be administered to a patient who has received a course of therapy with a pure opioid agonist analgesic as it decreases the analgesic effect by competitive blocking of the receptors, with the risk of appearance of a withdrawal syndrome.

+ Morphic Partial Antagonists (eg Naltrexone, Nalmefene)

Risk of reduction of the analgesic effect.

+ Sodium oxybate

Increased risk of respiratory depression, which can be fatal in case of overdose.

+ Monoamine oxidase inhibitors

MAOIs are known to interact with narcotic analgesics producing CNS excitation or depression with hyper- or hypotensive crisis. Morphine should not be co-administered with monoamine oxidase inhibitors or within two weeks of such therapy.

Concomitant use not recommended

+ Alcohol (drink or excipient)

Alcohol enhancement of the sedative effect of opioid analgesics.

Impaired alertness can make driving dangerous and the use of machinery dangerous.

Since alcohol may enhance the pharmacodynamic effects of Actimorph, concomitant use of alcohol or medicinal products containing alcohol and this medicinal product should be avoided.

+ Sedatives such as benzodiazepines or related medicinal products

The concomitant use of opioids with sedative medicinal products such as benzodiazepines or related medicinal products increases the risk of sedation, respiratory depression, coma and death because of additive CNS depressant effect. The dose and duration of concomitant use should be limited (see section 4.4).

Combinations subject to precautions for use

+ Rifampicin

Plasma concentrations and efficacy of morphine and its active metabolite may be reduced by rifampicin (see section 4.4). Clinical surveillance and possible adjustment of morphine dose are advisable during and after discontinuation of rifampicin.

+ Other agonist morphine analgesics (alfentanil, codeine, dextromoramide, dihydrocodeine, fentanyl, hydromorphone, oxycodone, pethidine, phenoperidine, remifentanil, sufentanil, tapentadol, tramadol)

Increased risk of respiratory depression, which can be fatal in case of overdose.

+ Morphine-like antitussives (eg dextromethorphan, noscapine, pholcodine)

Increased risk of respiratory depression, which can be fatal in case of overdose.

+ True morphine antitussives (eg codeine, ethylmorphine)

Increased risk of respiratory depression, which can be fatal in case of overdose.

+ Barbiturates (eg allobarbital, amobarbital, bartal, butalbital, butobarbital, hexobarbital, methylphenobarbital, phenobarbital, primidone, secbutabarbital, secobarbital, thiopental, vinbarbital, vinylbital)

Increased risk of respiratory depression, which can be fatal in case of overdose.

+ Other sedative medicinal products

Increase of the central depression. Impaired alertness can make driving dangerous and the use of machinery dangerous.

+ Anticholinergic medicinal products

Medicinal products that block the action of acetylcholine, for example atropine, antihistamines, anti-Parkinson's and anti-emetics, may interact with morphine to potentiate the anticholinergic adverse effects. Significant risk of colonic akinesia, with severe constipation.

+ P2Y12 inhibitors

A delayed and decreased exposure to oral P2Y12 inhibitor antiplatelet therapy has been observed in patients with acute coronary syndrome treated with morphine. This interaction may be related to reduced gastrointestinal motility and apply to other opioids. The clinical relevance is unknown, but data indicate the potential for reduced P2Y12 inhibitor efficacy in patients co-administered morphine and a P2Y12 inhibitor (see section 4.4). In patients with acute coronary syndrome, in whom morphine cannot be withheld and fast P2Y12 inhibition is deemed crucial, the use of a parenteral P2Y12 inhibitor may be considered.

+ Ritonavir

Although there are no pharmacokinetic data available for concomitant use of ritonavir with morphine, ritonavir induces the hepatic enzymes responsible for the glucuronidation of morphine, and may possibly decrease plasma concentrations of morphine.

+ Cimetidine

Cimetidine inhibits the metabolism of morphine.

4.6. Fertility, pregnancy and lactation

Pregnancy

In humans, there are no adequate data available to allow an evaluation of any potential teratogenic risk. There have been reports of a possible link to an increased incident of inguinal hernias. Morphine crosses the placental barrier. Animal studies showed a potential for damage in offspring throughout the entire duration of gestation (see section 5.3). For this reason, morphine must only be used during pregnancy in cases where the maternal benefit clearly outweighs the risk for the child.

Due to the mutagenic properties of morphine, it should not be administered to men and women of child-producing/child bearing potential unless effective contraception is assured.

Newborns whose mothers received opioid analgesics during pregnancy should be monitored for signs of neonatal withdrawal (abstinence) syndrome. Treatment may include an opioid and supportive care.

Parturition

Morphine can prolong or shorten the duration of labour. Neonates, whose mothers are given opioid analgesics during childbirth, should be monitored for signs of respiratory depression or withdrawal syndrome and (if necessary), treated with a specific opioid antagonist.

Breast-feeding

Morphine is excreted into breast milk, where it reaches higher concentrations than in maternal plasma. As clinically relevant concentrations may be reached in nursing infants, breast-feeding is not advised.

Fertility

Animal studies have shown that morphine may reduce fertility (see section 5.3).

4.7. Effects on ability to drive and use machines

Treatment with Actimorph Orodispersible tablets may cause sedation and it is not recommended that patients drive or use machines if they experience drowsiness. This medicinal product can impair cognitive function and can affect the patient's ability to drive safely mainly at treatment initiation, at any change of dose and in case of association with other central nervous system depressants such as alcohol or sedatives.

When the therapy is stabilized, a general driving ban is not mandatory.

4.8. Undesirable effects

In normal doses, the commonest undesirable effects of morphine are nausea, vomiting, confusion, constipation and drowsiness. With chronic therapy, nausea and vomiting are unusual with morphine but should they occur the orodispersible tablets can be readily combined with an anti-emetic if required. Constipation however does not stop while continuing the treatment. All these effects are predictable and need to be treated Constipation may be treated with appropriate laxatives.

The following frequencies are the basis for assessing undesirable effects:

Very common (≥1/10);

Common (≥ 1/100 to < 1/10);

Uncommon (≥ 1/1,000 to < 1/100);

Rare (≥ 1/10,000 to < 1/1,000);

Very rare (< 1/10,000);

Not known (cannot be estimated from the available data).

Systems Organ Classes

Very common

Common

Uncommon

Rare

Very Rare

Not known

Immune system disorders

Hypersensitivity

Anaphylactic reaction

Anaphylactoid reaction

Endocrine disorders

Syndrome of inadequate ADH-secretion (SIADH) (symptom: hyponatremia)

Metabolism and nutrition disorders

Decreased appetite

Psychiatric disorders

Mood altered, mostly Euphoria but also Dysphoria

Confusion

Insomnia

Changes in the activity (mostly decreased activity, but also hyperactivity or agitation)

Thinking disturbances

Cognitive disorders (e.g. hallucinations)

Libido decreased

Drug dependence (see section 4.4)

Nightmare (most often in elderly patients)

Nervous system disorders

Dizziness

Headache

Involuntary muscle contractions

Somnolence

Dysgeusia

Convulsions

Hypertonia

Myoclonus (in case of overdose or too fast dose increase in elderly or patients with kidney failure)

Paraesthesia

Syncope

Tremor

Sedation (dosage dependant)

Intracranial pressure increase, which should be treated at first

Allodynia

Hyperalgesia (see section 4.4)

Light-headedness

Eye disorders

Miosis

Nystagmus

Blurred vision

Double vision (diplopia)

Ear and labyrinth disorders

Vertigo

Cardiac disorders

Palpitations

Bradycardia

Tachycardia

Heart failure

Vascular disorders

Facial flushing

Hypotension

Hypertension

Hot flushes

Respiratory thoracic and mediastinal disorders

Bronchospasm

Pulmonary oedema

Respiratory depression (with apnoea at most)

Dyspnoea

Cough reflex decreased

Non-cardiogenic pulmonary oedema after rapid dose increase

Central sleep apnoea syndrome

Gastrointestinal disorders

Constipation

Nausea

Abdominal pain

Dry mouth

Vomiting (notably at treatment initiation)

Dyspepsia

Paralytic ileus

Pancreatitis (including exacerbation of pancreatitis)

Intestinal obstruction

Dental disease, but a causal relationship to morphine treatment cannot be established.

Hepatobiliary disorders

Biliary colic

Spasm of sphincter of Oddi

Skin and subcutaneous tissue disorders

Rash

Hyperhidrosis

Urticaria

Pruritus

Acute generalised exanthematous pustulosis (AGEP)

Musculoskeletal, connective tissue and bone diseases

Muscle spasms

Muscle rigidity

Renal and urinary disorders

Urinary retention (notably in case of prostatic adenoma or urethral stenosis)

Renal colic

Ureteric spasm

Dysuria

Reproductive system and breast disorders

Amenorrhoea

Erectile dysfunction

General disorders and administration site conditions

Asthenia

Fatigue

Malaise

Peripheral oedema

Shivers

Drug tolerance

Drug withdrawal (abstinence) syndrome

Drug withdrawal (abstinence) syndrome neonatal

Investigations

Hepatic enzymes increased

Description of selected adverse reactions

Drug dependence

Repeated sue of Actimorph can lead to drug dependence, even at therapeutic doses. Téhe risk of drug dependence may vary depending on a patient's individual risk factors, dosage, and duration of opioid treatment (see section 4.4).

Withdrawal (abstinence) syndrome:

An abstinence syndrome may be precipitated when opioid administration is suddenly discontinued or opioid antagonists administered, or can sometimes be experienced between doses. For management, see section 4.4.

Physiological withdrawal symptoms include: body aches, tremors, restless legs syndrome, diarrhoea, abdominal colic, nausea, flu-like symptoms, tachycardia and mydriasis. Psychological symptoms include dysphoric mood, anxiety and irritability. In drug dependence, “drug craving” is often involved.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9. Overdose

Symptoms

Toxic doses vary considerably with the individual, a single dose can lead to intoxication whereas regular users may tolerate large doses.

Signs of morphine toxicity and overdose are pin-point pupils (miosis), skeletal muscle flaccidity, bradycardia, hypotension, hypothermia, respiratory depression, pneumonia aspiration, somnolence and central nervous system depression which can progress to stupor or coma. Death may occur from respiratory failure. Circulatory failure and deepening coma may occur in more severe cases. Overdose can result in death. Rhabdomyolysis progressing to renal failure has been reported in opioid overdose.

Toxic leukoencephalopathy has been observed with morphine overdose.

Treatment of morphine overdose

Primary attention should be given to the establishment of a patent airway and institution of assisted or controlled ventilation.

The pure opioid antagonists are specific antidotes against the effects of opioid overdose. Other supportive measures should be employed as needed.

In unconscious patients with respiratory arrest, ventilation, intubation and intravenous administration of an opioid antagonist (eg 0.4-2 mg Naloxone i.v.) are indicated.

If respiratory failure persists, the single dose must be repeated 1 to 3 times at three-minute intervals until the respiratory rate is normalized and the patient responds to painful stimuli.

Strict monitoring (at least 24 hours) is necessary because the effect of the opioid antagonist is shorter than that of morphine, so that respiratory insufficiency can be expected to recur.

The dose of the opioid antagonist in children is 0.01 mg per kg body weight per single dose.

Measures to protect against heat loss and for volume therapy may also be required.

Naloxone should not be administered in the absence of clinically significant respiratory or circulatory depression secondary to morphine overdose. Naloxone should be administered cautiously to persons who are known, or suspected, to be physically dependent on morphine. In such cases, an abrupt or complete reversal of opioid effects may precipitate an acute withdrawal syndrome.

Oral activated charcoal (50 g) for adults, 1 g/kg for children) may be considered if a substantial amount has been ingested within one hour, provided the airway can be protected.

💬 Ask about this leaflet

Ask anything about Actimorph 5 mg Orodispersible tablets. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.

Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.

Pharmacies in major towns and cities — see the list
Pharmacies by county and region — see the full list

Browse all 2,009 towns and cities →